Our Pricing

Understanding Wegovy and Ozempic: The Same Active Ingredient, Different Purposes

Many UK patients ask about wegovy vs ozempic weight loss uk options, wondering if these medications are interchangeable. While both contain the same active ingredient—semaglutide—they are licensed for different purposes, formulated at different doses, and prescribed under different clinical criteria by UK healthcare professionals.

What Is the Difference Between Wegovy and Ozempic?

Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation and blood sugar control [1]. However, the Medicines and Healthcare products Regulatory Agency (MHRA) has licensed them for distinct therapeutic purposes in the UK.

Ozempic is licensed specifically for managing type 2 diabetes, helping patients improve glycaemic control alongside diet and exercise [2]. Wegovy, by contrast, is licensed exclusively for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension or dyslipidaemia [1].

The key distinction lies not in the molecule itself, but in the licensed indication, dosing schedule, and clinical context. Prescribing Ozempic for weight loss in non-diabetic patients would constitute off-label use, which UK prescribers typically avoid when a licensed alternative like Wegovy is available.

Wegovy vs Ozempic Dosing and Administration

Both medications are administered as once-weekly subcutaneous injections, but their dose escalation schedules differ to reflect their distinct therapeutic goals.

Wegovy follows a gradual titration protocol starting at 0.25 mg weekly, increasing every four weeks through 0.5 mg, 1 mg, and 1.7 mg, before reaching the maintenance dose of 2.4 mg weekly [1]. This higher maintenance dose is designed to maximise weight loss outcomes in patients without diabetes.

Ozempic, when used for type 2 diabetes, typically starts at 0.25 mg weekly for four weeks, then increases to 0.5 mg. Depending on glycaemic response, the dose may be increased to 1 mg or 2 mg weekly [2]. The maximum licensed dose for diabetes management is lower than Wegovy's maintenance dose, reflecting different treatment objectives.

Which Dose Is Right for Weight Loss?

Clinical trials demonstrate that higher semaglutide doses produce greater weight loss outcomes. In the STEP 1 trial, patients receiving 2.4 mg semaglutide weekly (the Wegovy dose) achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Your UK prescriber will determine the appropriate starting dose and titration schedule based on your medical history, current medications, and treatment goals during your clinical assessment.

Clinical Evidence: Wegovy and Ozempic for Weight Loss

The STEP clinical trial programme specifically evaluated semaglutide 2.4 mg (Wegovy) for weight management in adults without diabetes. STEP 1 enrolled 1,961 participants with obesity or overweight plus at least one weight-related comorbidity, demonstrating that 2.4 mg semaglutide produced significantly greater weight loss than placebo when combined with lifestyle intervention [1].

Participants receiving Wegovy lost an average of 14.9% of their initial body weight over 68 weeks, with 86.4% achieving at least 5% weight loss and 69.1% achieving at least 10% weight loss [1]. These outcomes established semaglutide 2.4 mg as one of the most effective pharmacological treatments for obesity available in the UK.

While Ozempic was not studied at the same doses in dedicated weight loss trials, observational data from diabetes trials showed that patients taking semaglutide for glycaemic control also experienced modest weight reduction—an effect that led to the development and licensing of Wegovy as a dedicated weight management treatment [2][3].

Side Effects and Safety Considerations

Because Wegovy and Ozempic contain the same active ingredient, they share a similar side effect profile. The most commonly reported adverse effects are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2].

In the STEP trials, approximately 74% of participants receiving semaglutide 2.4 mg reported at least one gastrointestinal adverse event, though most were mild to moderate in severity and diminished over time [1]. The gradual dose escalation schedule is designed to minimise these effects and improve tolerability.

Serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans) [1][2]. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your UK prescriber will review your full medical history during the clinical assessment to ensure semaglutide is safe and appropriate for you.

Managing Side Effects During Treatment

Most patients find that gastrointestinal side effects improve within the first few weeks of each dose increase. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help reduce nausea and discomfort. If side effects persist or become severe, your prescriber may recommend slowing the titration schedule or adjusting your dose. Never adjust your medication without consulting a healthcare professional.

Cost and Availability: Wegovy vs Ozempic in the UK

Both Wegovy and Ozempic are prescription-only medications in the UK and require a clinical assessment by a registered prescriber before they can be dispensed. At Cured Pharmacy, Wegovy is available from £79.00 following a free online consultation with our UK-registered clinical team, completed in under three minutes.

Pricing reflects the licensed indication, dose strength, and supply chain factors. Wegovy is specifically formulated and licensed for weight management, while Ozempic is licensed for type 2 diabetes. Attempting to source Ozempic for off-label weight loss may result in supply issues, as diabetes patients depend on consistent access to this medication.

Cured Pharmacy guarantees the lowest prices in the UK on genuine, UK-licensed medicines. All treatments are dispensed by our GPhC-registered pharmacy (registration number 9012511) under the oversight of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). Transparent upfront pricing means you see the cost before completing your consultation, with no hidden fees.

Which Treatment Should You Choose for Weight Loss?

For UK patients seeking pharmacological support for weight management, Wegovy is the appropriate licensed choice. It has been specifically studied, approved, and formulated for chronic weight management at the clinically effective 2.4 mg dose [1].

Ozempic, while containing the same active ingredient, is licensed for type 2 diabetes and prescribed at lower maintenance doses. Using Ozempic off-label for weight loss is generally discouraged by UK prescribers when Wegovy—a licensed, evidence-based alternative—is available.

Your clinical assessment will consider your BMI, weight-related health conditions, previous weight loss attempts, current medications, and treatment goals. Our UK prescribers will recommend the most appropriate treatment based on NICE guidance, MHRA licensing, and your individual circumstances. If you have type 2 diabetes and obesity, your prescriber will evaluate whether Ozempic, Wegovy, or another medication is most suitable.

Starting Your Weight Loss Journey at Cured Pharmacy

Begin with a free online consultation that takes under three minutes to complete. Our UK-registered prescribers will review your medical history and determine whether Wegovy is clinically appropriate for you. If approved, your medication is dispensed from our GPhC-registered pharmacy and delivered discreetly to your door. Ongoing support and follow-up consultations ensure you achieve the best possible outcomes safely.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., et al. (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA, 318(15), 1460–1470. https://doi.org/10.1001/jama.2017.14752
3. Pratley, R. E., Aroda, V. R., Lingvay, I., et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275–286. https://doi.org/10.1016/S2213-8587(18)30024-X

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.